[
  {
    "ts": null,
    "headline": "Johnson & Johnson shrugs off tariff impact and forecasts sales boost",
    "summary": "Johnson & Johnson has shrugged off the impact of tariffs as the US-based healthcare group raised its earnings and sales guidance for 2025. J...",
    "url": "https://finnhub.io/api/news?id=682785971e5c5fd91bbbdc36c049d3f2dd070d4a886b35947d140bf1cc92d0a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752661507,
      "headline": "Johnson & Johnson shrugs off tariff impact and forecasts sales boost",
      "id": 135965004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Johnson & Johnson has shrugged off the impact of tariffs as the US-based healthcare group raised its earnings and sales guidance for 2025. J...",
      "url": "https://finnhub.io/api/news?id=682785971e5c5fd91bbbdc36c049d3f2dd070d4a886b35947d140bf1cc92d0a8"
    }
  },
  {
    "ts": null,
    "headline": "Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)",
    "summary": "Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed’s comment followed reports that Health and Human Services Secretary Kennedy was considering a review of licensed vaccines containing aluminum adjuvants. The […]",
    "url": "https://finnhub.io/api/news?id=8787991a12031f54d8c727f11cd2dcba272759e78914fdee7fc0e912b6deb59c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752673138,
      "headline": "Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)",
      "id": 135967687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed’s comment followed reports that Health and Human Services Secretary Kennedy was considering a review of licensed vaccines containing aluminum adjuvants. The […]",
      "url": "https://finnhub.io/api/news?id=8787991a12031f54d8c727f11cd2dcba272759e78914fdee7fc0e912b6deb59c"
    }
  },
  {
    "ts": null,
    "headline": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
    "summary": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
    "url": "https://finnhub.io/api/news?id=97ab44abf5ee1b1e0d567b77c8e08918c45866d82561979061d15f1dab32bc80",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669900,
      "headline": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
      "id": 135975027,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
      "url": "https://finnhub.io/api/news?id=97ab44abf5ee1b1e0d567b77c8e08918c45866d82561979061d15f1dab32bc80"
    }
  },
  {
    "ts": null,
    "headline": "Mamdani Talks ‘Intifada’, Taxes in Grilling by Business Leaders",
    "summary": "(Bloomberg) -- New York City mayoral candidate Zohran Mamdani told business leaders that he would begin to discourage the use of the phrase “globalize the intifada” after being pressed on his views by Pfizer Inc. chief executive Albert Bourla, according to people with knowledge of the matter.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearManhatta",
    "url": "https://finnhub.io/api/news?id=dda02f498ec2ed112c73ff30a0ae3a685cadd21efbd996909ee63d1ae8c69bed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752664795,
      "headline": "Mamdani Talks ‘Intifada’, Taxes in Grilling by Business Leaders",
      "id": 135964814,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- New York City mayoral candidate Zohran Mamdani told business leaders that he would begin to discourage the use of the phrase “globalize the intifada” after being pressed on his views by Pfizer Inc. chief executive Albert Bourla, according to people with knowledge of the matter.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homelessness Drops for Second YearManhatta",
      "url": "https://finnhub.io/api/news?id=dda02f498ec2ed112c73ff30a0ae3a685cadd21efbd996909ee63d1ae8c69bed"
    }
  },
  {
    "ts": null,
    "headline": "Will Increased Expenses Affect Bristol Myers' Performance?",
    "summary": "BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.",
    "url": "https://finnhub.io/api/news?id=26b85ad65875faabc2cf17723e2b11cad625d21da4b7d94680d13a62398a9cc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669660,
      "headline": "Will Increased Expenses Affect Bristol Myers' Performance?",
      "id": 135993392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.",
      "url": "https://finnhub.io/api/news?id=26b85ad65875faabc2cf17723e2b11cad625d21da4b7d94680d13a62398a9cc3"
    }
  },
  {
    "ts": null,
    "headline": "How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?",
    "summary": "ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.",
    "url": "https://finnhub.io/api/news?id=794b7a8719fabfd42c7d66b74bfaa85f5cb7149999cdcfea6e06bd67ac23205a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669540,
      "headline": "How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?",
      "id": 135993161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.",
      "url": "https://finnhub.io/api/news?id=794b7a8719fabfd42c7d66b74bfaa85f5cb7149999cdcfea6e06bd67ac23205a"
    }
  },
  {
    "ts": null,
    "headline": "Wedgewood Partners Q2 2025 Client Letter",
    "summary": "Top performance contributors for the first quarter include Taiwan Semiconductor Manufacturing, Meta Platforms, Microsoft, Booking Holdings and Alphabet.",
    "url": "https://finnhub.io/api/news?id=5bed2d36b9ce9ce05faabdc5a59ba08737e800ebaca68344def5ea4ead8ab72f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752666000,
      "headline": "Wedgewood Partners Q2 2025 Client Letter",
      "id": 135969420,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2216403509/image_2216403509.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Top performance contributors for the first quarter include Taiwan Semiconductor Manufacturing, Meta Platforms, Microsoft, Booking Holdings and Alphabet.",
      "url": "https://finnhub.io/api/news?id=5bed2d36b9ce9ce05faabdc5a59ba08737e800ebaca68344def5ea4ead8ab72f"
    }
  },
  {
    "ts": null,
    "headline": "This Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?",
    "summary": "Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.",
    "url": "https://finnhub.io/api/news?id=68b43b8b7273a49533e77fd879cc1ac778337327540f367fe2bfcce1a2c8fdd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752665402,
      "headline": "This Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?",
      "id": 135965222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.",
      "url": "https://finnhub.io/api/news?id=68b43b8b7273a49533e77fd879cc1ac778337327540f367fe2bfcce1a2c8fdd0"
    }
  },
  {
    "ts": null,
    "headline": "Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda",
    "summary": "Today, PODD: Partnership Opportunities in Drug Delivery – the leading event reporting on key developments in drug delivery technologies – announced the agenda and featured sessions for its 15th annual conference, which will take place on October 27-28 at the Westin Copley Place in Boston, MA.",
    "url": "https://finnhub.io/api/news?id=c65bcd8c51903f1a8a5189ec08d59e1b302390bb394211f3d978609828009681",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752664200,
      "headline": "Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda",
      "id": 135964839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Today, PODD: Partnership Opportunities in Drug Delivery – the leading event reporting on key developments in drug delivery technologies – announced the agenda and featured sessions for its 15th annual conference, which will take place on October 27-28 at the Westin Copley Place in Boston, MA.",
      "url": "https://finnhub.io/api/news?id=c65bcd8c51903f1a8a5189ec08d59e1b302390bb394211f3d978609828009681"
    }
  },
  {
    "ts": null,
    "headline": "Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy.",
    "summary": "Trump has again threatened the multibillion-dollar pharmaceutical sector with high tariffs unless they move production to the U.S.",
    "url": "https://finnhub.io/api/news?id=448f593dcc2fcaff7ce0f76ae6948953b4e572c7fe3374e6435eac06eeae5e30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752662100,
      "headline": "Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy.",
      "id": 135964841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Trump has again threatened the multibillion-dollar pharmaceutical sector with high tariffs unless they move production to the U.S.",
      "url": "https://finnhub.io/api/news?id=448f593dcc2fcaff7ce0f76ae6948953b4e572c7fe3374e6435eac06eeae5e30"
    }
  },
  {
    "ts": null,
    "headline": "This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback",
    "summary": "A few years ago, Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance.  This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous levels of revenue.",
    "url": "https://finnhub.io/api/news?id=1cf4689e38dc9e71354f5964be85635359fd6373ae1b86f62cb45f672448ac14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752653520,
      "headline": "This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback",
      "id": 135965495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A few years ago, Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance.  This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous levels of revenue.",
      "url": "https://finnhub.io/api/news?id=1cf4689e38dc9e71354f5964be85635359fd6373ae1b86f62cb45f672448ac14"
    }
  },
  {
    "ts": null,
    "headline": "Mamdani Clarifies ‘Globalize the Intifada’ Stance in Meeting With Business Elites",
    "summary": "Zohran Mamdani  said he would discourage the use of the slogan “globalize the intifada” in a roughly hourlong meeting with some of New York City’s most powerful executives on Tuesday, seeking to defuse an issue that has prompted a backlash from the business community and beyond.  Mamdani, the Democratic nominee for New York City mayor, was questioned by a room of more than 100 executives at an event hosted by the Partnership for New York City, an influential business group.  Pfizer Chief Executive Officer  Albert Bourla  and  Robert Speyer,  CEO of the real-estate firm Tishman Speyer, moderated the event, which also included questions from the audience.",
    "url": "https://finnhub.io/api/news?id=aa9906436e6a43044fa2ad0a523dcff3a34145d27fa2df63058bf5d62e97a3f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752624480,
      "headline": "Mamdani Clarifies ‘Globalize the Intifada’ Stance in Meeting With Business Elites",
      "id": 135965496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zohran Mamdani  said he would discourage the use of the slogan “globalize the intifada” in a roughly hourlong meeting with some of New York City’s most powerful executives on Tuesday, seeking to defuse an issue that has prompted a backlash from the business community and beyond.  Mamdani, the Democratic nominee for New York City mayor, was questioned by a room of more than 100 executives at an event hosted by the Partnership for New York City, an influential business group.  Pfizer Chief Executive Officer  Albert Bourla  and  Robert Speyer,  CEO of the real-estate firm Tishman Speyer, moderated the event, which also included questions from the audience.",
      "url": "https://finnhub.io/api/news?id=aa9906436e6a43044fa2ad0a523dcff3a34145d27fa2df63058bf5d62e97a3f6"
    }
  }
]